Clinical Trials on Burn Infection in Sweden

Total 859 results

AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE2)

Psoriatic Arthritis (PsA)

United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, United...
AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)

Psoriatic Arthritis

United States, Argentina, Australia, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, Estonia, Finland, Germany, Greece, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico and more
Shire

Completed

Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase

Hunter Syndrome | Mucopolysaccharidosis II (MPS II)

United States, France, United Kingdom, Germany, Sweden, Spain, Brazil, Canada, Italy, Romania
Amgen

Active, not recruiting

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke (VESALIUS-CV)

Coronary Heart Disease (CHD)

Canada, France, United States, Spain, United Kingdom, Korea, Republic of, Netherlands, Austria, Australia, Czechia, Taiwan, Finland, Hungary, Italy, Poland, Greece, Germany, Brazil, Latvia, Denmark, Mexico, Russian Federation, Bulgaria and more
Cogentus Pharmaceuticals

Terminated

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1) (COGENT-1)

Myocardial Infarction | Coronary Artery Disease | Acute Coronary Syndrome | Percutaneous Coronary Intervention

United States, France, Canada, Australia, Poland, Germany, Italy, Mexico, Romania, Slovakia, Hungary, Czech Republic, Chile, Bulgaria, Puerto Rico, Ukraine
AbbVie (prior sponsor, Abbott)

Completed

Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis in Normal Medical Practice

Psoriatic Arthritis

Germany
Incyte Corporation

Terminated

GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

Chronic Graft-versus-host Disease

United States, Spain, France, Canada, Israel, United Kingdom, Germany, Italy, Denmark, Sweden, Finland, Belgium, Poland, Greece, Austria, Switzerland
BioNTech SE

Recruiting

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT)

Recurrent Head and Neck Cancer | Unresectable Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Cancer

Germany, United States, France, United Kingdom, Korea, Republic of, Spain, Poland, Belgium, Brazil, Taiwan, Italy, Canada, Czechia, Australia, Turkey, Mexico, Chile, Argentina, Austria, Hungary, Portugal, Sweden
Janssen Research & Development, LLC
Pharmacyclics LLC.

Enrolling by invitation

A Long-term Extension Study of PCI-32765 (Ibrutinib) (CAN3001)

Follicular Lymphoma | Chronic Graft Versus Host Disease | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Small Lymphocytic Lymphoma

United States, Spain, United Kingdom, Israel, Canada, Belgium, Poland, China, Japan, France, Australia, Russian Federation, Turkey, Sweden, Italy, Mexico, Czechia, Korea, Republic of, Ukraine, Brazil, Hungary, Portugal, Argentina, Col... and more

Clinical Trials on Burn Infection in Sweden

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations